270 related articles for article (PubMed ID: 27890237)
1. Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.
Nathan N; Keppler-Noreuil KM; Biesecker LG; Moss J; Darling TN
Dermatol Clin; 2017 Jan; 35(1):51-60. PubMed ID: 27890237
[TBL] [Abstract][Full Text] [Related]
2. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.
Keppler-Noreuil KM; Parker VE; Darling TN; Martinez-Agosto JA
Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):402-421. PubMed ID: 27860216
[TBL] [Abstract][Full Text] [Related]
3. Development of hypomelanotic macules is associated with constitutive activated mTORC1 in tuberous sclerosis complex.
Møller LB; Schönewolf-Greulich B; Rosengren T; Larsen LJ; Ostergaard JR; Sommerlund M; Ostenfeldt C; Stausbøl-Grøn B; Linnet KM; Gregersen PA; Jensen UB
Mol Genet Metab; 2017 Apr; 120(4):384-391. PubMed ID: 28336152
[TBL] [Abstract][Full Text] [Related]
4. A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K/AKT/mTOR signaling pathway.
Fu J; Liang P; Zheng Y; Xu C; Xiong F; Yang F
Gene; 2024 May; 909():148312. PubMed ID: 38412945
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
6. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.
Tanwar PS; Kaneko-Tarui T; Zhang L; Tanaka Y; Crum CP; Teixeira JM
PLoS Genet; 2012; 8(8):e1002906. PubMed ID: 22916036
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
[TBL] [Abstract][Full Text] [Related]
8. Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel.
Chang F; Liu L; Fang E; Zhang G; Chen T; Cao K; Li Y; Li MM
J Mol Diagn; 2017 Jul; 19(4):613-624. PubMed ID: 28502725
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift.
Medvetz D; Priolo C; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):3-8. PubMed ID: 25298408
[TBL] [Abstract][Full Text] [Related]
10. Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.
Han S; Polizzano C; Nielsen GP; Hornicek FJ; Rosenberg AE; Ramesh V
Clin Cancer Res; 2009 Mar; 15(6):1940-6. PubMed ID: 19276265
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Davis NM; Sokolosky M; Stadelman K; Abrams SL; Libra M; Candido S; Nicoletti F; Polesel J; Maestro R; D'Assoro A; Drobot L; Rakus D; Gizak A; Laidler P; Dulińska-Litewka J; Basecke J; Mijatovic S; Maksimovic-Ivanic D; Montalto G; Cervello M; Fitzgerald TL; Demidenko Z; Martelli AM; Cocco L; Steelman LS; McCubrey JA
Oncotarget; 2014 Jul; 5(13):4603-50. PubMed ID: 25051360
[TBL] [Abstract][Full Text] [Related]
12. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
[TBL] [Abstract][Full Text] [Related]
13. Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.
Gao Y; Gartenhaus RB; Lapidus RG; Hussain A; Zhang Y; Wang X; Dan HC
Mol Cancer Res; 2015 Dec; 13(12):1602-14. PubMed ID: 26374334
[TBL] [Abstract][Full Text] [Related]
14. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
Hino O; Kobayashi T
Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
[TBL] [Abstract][Full Text] [Related]
15. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
[TBL] [Abstract][Full Text] [Related]
16. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
[TBL] [Abstract][Full Text] [Related]
17. Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway.
Akgumus G; Chang F; Li MM
J Mol Diagn; 2017 Jul; 19(4):487-497. PubMed ID: 28502730
[TBL] [Abstract][Full Text] [Related]
18. Low-level mosaicism in tuberous sclerosis complex in four unrelated patients: Comparison of clinical characteristics and diagnostic pathways.
Manzanilla-Romero HH; Weis D; Schnaiter S; Rudnik-Schöneborn S
Am J Med Genet A; 2021 Dec; 185(12):3851-3858. PubMed ID: 34328706
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of four Mendelian disorders associated with autism in 2392 affected families.
Saskin A; Fulginiti V; Birch AH; Trakadis Y
J Hum Genet; 2017 Jun; 62(6):657-659. PubMed ID: 28250423
[TBL] [Abstract][Full Text] [Related]
20. Structure of the Tuberous Sclerosis Complex 2 (TSC2) N Terminus Provides Insight into Complex Assembly and Tuberous Sclerosis Pathogenesis.
Zech R; Kiontke S; Mueller U; Oeckinghaus A; Kümmel D
J Biol Chem; 2016 Sep; 291(38):20008-20. PubMed ID: 27493206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
